AI MARKET SCANNING

C4 Therapeutics, Inc.

📅 Next Catalyst: Nov 05, 2026 (☀️ Open) 🏛️ NASDAQ 📁 Healthcare 🏭 Biotechnology
AVG HISTORICAL GAP +1.70%
MAX GAP RECORD +10.64%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $CCCC
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 05, 2026 Earnings Release 2026-11-05 (BEFORE OPEN (07:00)) 🔮 UPCOMING 🔒
Aug 11, 2026 Earnings Release 2026-08-11 (BEFORE OPEN)
+6.08%
May 12, 2026 Earnings Release 2026-05-12 (BEFORE OPEN)
-2.84%
Feb 26, 2026 Earnings Release 2026-02-26 (BEFORE OPEN)
+5.78%
Nov 06, 2025 Earnings Release 2025-11-06 (BEFORE OPEN)
-0.84%
Aug 07, 2025 Earnings Release 2025-08-07 (BEFORE OPEN)
+2.04%
May 07, 2025 Earnings Release 2025-05-07 (BEFORE OPEN)
+10.64%
Feb 27, 2025 Earnings Release 2025-02-27 (BEFORE OPEN)
-0.75%

VOLATILITY & GAP BIAS

AVG GAP MOVE 3.0%
Bullish Gaps (6)
Bearish Gaps (3)
Neutral / Flat (4)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $CCCC

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1. The…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗